💨 Abstract

Indian drugmakers, led by Dr Reddy's, anticipate staying competitive in the generic drugs market despite potential U.S. tariffs on pharmaceutical imports, according to Dr GV Prasad. The Indian pharmaceutical industry is awaiting further clarity on any tariffs due to a lack of details. Tariffs could increase costs for U.S. consumers or intermediaries but shifting all global production to the U.S.

Courtesy: theprint.in

Summarized by Einstein Beta 🤖